Eszopiclone Treatment for Menopausal Sleep Disturbances

Solution Overview

Problem

Current treatments for menopause and perimenopause symptoms, such as hot flashes and sleep disturbances, often come with undesirable side effects, and there is a need for a safe and effective alternative to hormone therapy.

Innovation Solution

Administering eszopiclone, a cyclopyrrolone with a high enantiomeric excess, orally or parenterally, in doses ranging from 0.5 mg to 15 mg daily, to alleviate symptoms associated with menopause and perimenopause, including hot flashes and sleep disturbances.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If hormone therapy is used to treat menopause and perimenopause symptoms, then symptom relief is achieved, but undesirable side effects occur

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameter from hormone-based therapy to eszopiclone (a cyclopyrrolone derivative), fundamentally altering the therapeutic agent's molecular structure and mechanism of action. This parameter change allows achieving symptom relief through a non-hormonal pathway that avoids hormone-related side effects

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs eszopiclone as a short-acting alternative to long-term hormone therapy, providing symptom relief on demand with a half-life of approximately 6 hours, thereby avoiding the cumulative side effects associated with prolonged hormone exposure

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

2Reliability

If eszopiclone is administered at higher doses to improve symptom relief, then therapeutic effectiveness increases, but safety margin decreases

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs partial action by administering eszopiclone at low doses (0.5-3 mg daily) that are sufficient to achieve the desired therapeutic effect for menopause symptoms without exceeding the threshold that would cause adverse effects. This partial action principle optimizes the balance between efficacy and safety

Inventive Principle:
Principle #16Partial or excessive action

Solution Approach 2:

The patent utilizes periodic administration of eszopiclone, typically once daily or as needed for symptom management, allowing the drug to be cleared from the system before the next dose. This periodic action maintains therapeutic effectiveness while preventing accumulation that could compromise safety

Inventive Principle:
Principle #19Periodic action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Eszopiclone effectively decreases nocturnal awakenings due to hot flashes and overall menopausal or perimenopausal symptoms, as demonstrated in clinical studies, with a high safety margin and minimal cardiovascular or autonomic effects.

Implementation Method 1

The compound binds to the benzodiazepine receptor complex, or to a site linked closely to this receptor complex... suggesting that benzodiazepines and chemically unrelated agonists including zopiclone may exert their effects by facilitating the synaptic effects of GABA

Methodology Applied
Scientific EffectReceptor binding:

Data Source

PatentUS7465729B2Methods of treatment of menopause and perimenopause using eszopiclone
Publication Date: 2008.12.16
  • US7465729B2 patent drawing
  • US7465729B2 patent drawing
  • US7465729B2 patent drawing

AI summary

The invention relates to the use of eszopiclone for the treatment of symptoms accompanying perimenopause or menopause.